Treatment of anthracycline extravasation with dexrazoxane

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3680-3686

  Langer, S W ^a   Sehested, M ^a   Jensen, P B ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GYRASE INHIBITOR; IDARUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFECT; DRUG EXTRAVASATION; DRUG USE; EXTRAVASATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WOUND;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME INHIBITORS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; IDARUBICIN; MICE; RAZOXANE; SKIN DISEASES;

EID: 0033817796     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Treatment of tissue extravasation by antitumor agents
2. Treatment methods for extravasations of chemotherapeutic agents: A comparative study
3. The management of inadvertent subcutaneous Adriamycin infiltration
4. Antimmor agents: Extravasation, management, and surgical treatment
5. Adriamycin extravasation
6. Long persistence of doxorubicin in human skin after extravasation
7. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach
8. Amelioration of Adriamycin skin necrosis: An experimental study
9. The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse
10. Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention
11. Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rat
12. Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat
13. Extravasation of dactinomycin, vincristine, and cisplatin: Studies in an animal model
14. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes
15. Prevention of Adriamycin-induced full-thickness skin loss using hyaluronidase infiltration
16. Modulation of experimental doxorubicin skin toxicity by β-adrenergic compounds
17. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study
18. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation
19. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse
20. Doxorubicin-induced skin necrosis in the swine model: Protection with a novel radical dimer
21. Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound
22. Cancer chemotherapy agent-induced perivenous extravasation injuries
23. Cytostatic extravasations
24. Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. Experimental and clinical studies
25. Catalytic inhibitors of DNA topoisomerase II
26. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
27. Inhibition of intracellular topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
28. Antagonistic effect of the cardioprotector (+)-1,2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
29. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
30. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of Adriamycin
31. The iron(III) and copper(II) complexes of Adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3, 5-dioxopiperazinyl-1-yl)propane)
32. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159; a Tyr49Phe mutation confers high level resistance to bisdioxopiperazines
33. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the α isoform
34. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs
35. Experimental skin necrosis produced by Adriamycin
36. An HPLC and spectrometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its openring hydrolysis intermediates
37. Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy
38. Phase I study of ICRF-187 using a daily for 3 days schedule
39. Experience with subcutaneous infusion ports in three hundred patients
40. Extravasation of doxorubicin from vascular access devices (see comments)